Question · asked by 1 review
Palmitoylethanolamide and luteolin vs no intervention: Generic quality of life measures
- Population
- adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
- Intervention
- Palmitoylethanolamide and luteolin
- Comparison
- no intervention
- Outcome
- Generic quality of life measures
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Palmitoylethanolamide and luteolin vs no intervention Generic quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection The review found no eligible studies for this question. Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.